Luis Borges
Directeur Technique/Scientifique/R&D chez METAGENOMI, INC.
Fortune : 1 M $ au 30/04/2024
Profil
Luis G.
Borges is currently the Chief Scientific Officer at Metagenomi, Inc. He previously worked as the Chief Scientific Officer at Century Therapeutics, Inc. from 2019 to 2023.
Prior to that, he was the Senior Vice President-Research at Five Prime Therapeutics, Inc. from 2017 to 2019 and the Chief Scientific Officer at Kuur Therapeutics Ltd.
from 2017 to 2019.
He also worked as the Scientific Director at Amgen, Inc. from 2011 to 2014.
Borges has an undergraduate degree from the University of Lisbon and a doctorate from the University of Washington.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 03/04/2023 | 256 535 ( 0,40% ) | 808 085 $ | 30/04/2024 | |
METAGENOMI, INC.
0,18% | 01/04/2024 | 69 316 ( 0,18% ) | 467 190 $ | 30/04/2024 |
Postes actifs de Luis Borges
| Sociétés | Poste | Début |
|---|---|---|
| METAGENOMI, INC. | Directeur Technique/Scientifique/R&D | 01/08/2023 |
Anciens postes connus de Luis Borges
| Sociétés | Poste | Fin |
|---|---|---|
| CENTURY THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | 01/07/2023 |
| FIVE PRIME THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | 01/03/2019 |
Kuur Therapeutics Ltd.
 Kuur Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Kuur Therapeutics provides clinical cellular therapeutics services. It develops, manufactures and markets personalized cellular immunotherapeutics for infectious disease and cancer. Cell Medica has developed proprietary production technology enabling GMP compliant manufacture of antigen-specific T cells. The company was founded by Gregg Sando in 2006 and is headquartered in London, the United Kingdom. | Directeur Technique/Scientifique/R&D | 01/03/2019 |
| AMGEN INC. | Directeur Technique/Scientifique/R&D | 01/04/2014 |
Formation de Luis Borges
| University of Washington | Doctorate Degree |
| University of Lisbon | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| AMGEN INC. | Health Technology |
| CENTURY THERAPEUTICS, INC. | Health Technology |
| METAGENOMI, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Five Prime Therapeutics, Inc.
 Five Prime Therapeutics, Inc. BiotechnologyHealth Technology Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of novel protein therapeutics. Its product candidates includes, Cabiralizumab (FPA008), Bemarituzumab (FPA144), and FPA150. The FPA008 is an antibody that inhibits colony stimulating factor-1, or CSF1, receptor, or CSF1R, that are developing in rheumatoid arthritis and plan to clinically develop in pigmented villonodular synovitis, or PVNS, and in combination with nivolumab in multiple cancers. The FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that are developing to treat patients with gastric cancer. The FPA150 is a CD8 T cell checkpoint which targets B7-H4 that is developing as a monotherapy in multiple cancers. The company was founded by Lewis T. Williams in December 2001 and is headquartered in South San Francisco, C. | Health Technology |
Kuur Therapeutics Ltd.
Kuur Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Kuur Therapeutics provides clinical cellular therapeutics services. It develops, manufactures and markets personalized cellular immunotherapeutics for infectious disease and cancer. Cell Medica has developed proprietary production technology enabling GMP compliant manufacture of antigen-specific T cells. The company was founded by Gregg Sando in 2006 and is headquartered in London, the United Kingdom. | Health Technology |
Metagenomi Technologies LLC
 Metagenomi Technologies LLC BiotechnologyHealth Technology Metagenomi Technologies LLC engages in the development of curative therapeutics and gene-editing technologies and therapies. The company was founded by Brian C. Thomas in September 2016 and is headquartered in Emeryville, CA. | Health Technology |
